Published in BMC Cancer on July 27, 2011
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract (2012) 1.36
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc (2014) 1.18
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2013) 0.86
Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment. Front Oncol (2014) 0.85
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. Biomed Res Int (2015) 0.81
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat (2015) 0.80
Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail (2016) 0.79
Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev (2015) 0.79
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovasc Ultrasound (2015) 0.77
Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manag (2015) 0.76
Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? Ecancermedicalscience (2014) 0.76
Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open (2016) 0.75
Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Med Oncol (2016) 0.75
Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials. Indian J Pharmacol (2016) 0.75
Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol (2016) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol (2000) 7.17
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol (2010) 5.99
A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer (1973) 5.51
Biomarkers in heart failure. N Engl J Med (2008) 5.20
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J (2000) 4.99
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation (2005) 3.86
A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol (2007) 3.16
Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol (2007) 3.00
Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2000) 2.85
Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med (1997) 2.81
Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation (1995) 2.78
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 2.72
Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol (2007) 2.53
Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol (2006) 2.52
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol (2005) 1.92
Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation (2000) 1.82
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol (2002) 1.78
The tumor metabolome. Anticancer Res (2003) 1.68
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol (2000) 1.66
Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med (2006) 1.65
Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist (2006) 1.65
Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation (2010) 1.62
Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res (2010) 1.42
Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J (2008) 1.28
Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med (2007) 1.13
Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail (2004) 1.10
Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat (2008) 1.08
Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res (2009) 1.04
Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis (2010) 1.00
A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail (2006) 0.90
Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart (2004) 0.88
Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease? J Cardiovasc Med (Hagerstown) (2009) 0.80
Troponin I and cardiovascular risk stratification in patients with testicular cancer. J Clin Oncol (2006) 0.77
Genomics in cardiac metabolism. Cardiovasc Res (2008) 0.77
Magnetic resonance imaging in cardiology. J R Coll Physicians Lond (1999) 0.77
Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol (2009) 6.41
Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ (2006) 4.79
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
Gastric adenocarcinoma: review and considerations for future directions. Ann Surg (2005) 3.83
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol (2007) 3.58
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol (2003) 3.56
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res (2009) 3.06
Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA (2007) 2.93
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res (2012) 2.83
Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation (2003) 2.75
Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol (2007) 2.65
Measuring picomolar intracellular exchangeable zinc in PC-12 cells using a ratiometric fluorescence biosensor. ACS Chem Biol (2006) 2.56
Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol (2007) 2.53
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol (2006) 2.51
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J (2013) 2.27
The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer (2003) 2.24
Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 2.23
Exercise training improves overall physical fitness and quality of life in older women with coronary artery disease. Chest (2004) 2.21
Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol (2005) 2.11
Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation (2002) 2.08
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med (2004) 2.04
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99
Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax (2012) 1.95
Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev (2003) 1.89
Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol (2008) 1.79
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol (2010) 1.74
Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping. Magn Reson Med (2013) 1.69
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Res Treat (2010) 1.65
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer (2007) 1.63
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem (2005) 1.62
Synthetic mimetics of actin-binding macrolides: rational design of actin-targeted drugs. Chem Biol (2008) 1.61
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol (2012) 1.61
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol (2004) 1.60
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 1.59
Advances in the total synthesis of biologically important marine macrolides. Chem Rev (2005) 1.58
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Cardiovascular fitness and mortality after contemporary cardiac rehabilitation. Mayo Clin Proc (2013) 1.56
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. Oncologist (2011) 1.52
Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? J Clin Oncol (2011) 1.48
Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav Immun (2005) 1.45
Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol (2014) 1.43
Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions. Cancer (2007) 1.41
Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J Physiol (2012) 1.37
Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol (2006) 1.36
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol (2008) 1.33
Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer (2009) 1.32
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation (2011) 1.30
Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol (1985) (2005) 1.29
A meta-analysis of randomized control trials of home-based secondary prevention programs for coronary artery disease. Eur J Cardiovasc Prev Rehabil (2010) 1.28
Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology (2014) 1.28
Actin-binding marine macrolides: total synthesis and biological importance. Angew Chem Int Ed Engl (2002) 1.24
Invasive human magnetic resonance imaging: feasibility during revascularization in a combined XMR suite. Catheter Cardiovasc Interv (2005) 1.23
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Predictors of supervised exercise adherence during breast cancer chemotherapy. Med Sci Sports Exerc (2008) 1.23
The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat (2004) 1.22
Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res (2009) 1.21
Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem (2004) 1.20
Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res (2010) 1.19
Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure. CMAJ (2013) 1.19
Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer (2006) 1.19
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst (2013) 1.18
The bound conformation of microtubule-stabilizing agents: NMR insights into the bioactive 3D structure of discodermolide and dictyostatin. Chemistry (2008) 1.18
Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. Cancer (2002) 1.18
Synaptic release of zinc from brain slices: factors governing release, imaging, and accurate calculation of concentration. J Neurosci Methods (2006) 1.17
Exercise for breast cancer survivors: research evidence and clinical guidelines. Phys Sportsmed (2002) 1.16
Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. Am Heart J (2012) 1.16
Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Ann Behav Med (2008) 1.16
Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer (2008) 1.15
T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging (2013) 1.15
Analyzing theoretical mechanisms of physical activity behavior change in breast cancer survivors: results from the activity promotion (ACTION) trial. Ann Behav Med (2008) 1.15
Depletion of intracellular zinc from neurons by use of an extracellular chelator in vivo and in vitro. J Histochem Cytochem (2002) 1.14
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Real-time magnetic resonance-guided endovascular repair of experimental abdominal aortic aneurysm in swine. J Am Coll Cardiol (2005) 1.12
Real-time magnetic resonance imaging-guided stenting of aortic coarctation with commercially available catheter devices in Swine. Circulation (2005) 1.11
Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail (2012) 1.11
Free zinc ions outside a narrow concentration range are toxic to a variety of cells in vitro. Exp Biol Med (Maywood) (2010) 1.10
Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy. Breast Cancer Res Treat (2008) 1.10
Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin Cancer Res (2005) 1.09